These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

239 related articles for article (PubMed ID: 28874443)

  • 1. Amelioration of diet-induced steatohepatitis in mice following combined therapy with ASO-Fsp27 and fenofibrate.
    Rajamoorthi A; Arias N; Basta J; Lee RG; Baldán Á
    J Lipid Res; 2017 Nov; 58(11):2127-2138. PubMed ID: 28874443
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeted Delivery of Stk25 Antisense Oligonucleotides to Hepatocytes Protects Mice Against Nonalcoholic Fatty Liver Disease.
    Cansby E; Nuñez-Durán E; Magnusson E; Amrutkar M; Booten SL; Kulkarni NM; Svensson LT; Borén J; Marschall HU; Aghajan M; Mahlapuu M
    Cell Mol Gastroenterol Hepatol; 2019; 7(3):597-618. PubMed ID: 30576769
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Periostin antisense oligonucleotide prevents hepatic steatosis and fibrosis in a mouse model of non-alcoholic steatohepatitis.
    Kobayashi T; Kanno K; Nguyen PT; Sugiyama A; Kawahara A; Otani Y; Kishikawa N; Ito M; Tazuma S
    J Gastroenterol Hepatol; 2020 Dec; 35(12):2140-2150. PubMed ID: 32365405
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Therapeutic silencing of FSP27 reduces the progression of atherosclerosis in Ldlr
    Rajamoorthi A; Lee RG; Baldán Á
    Atherosclerosis; 2018 Aug; 275():43-49. PubMed ID: 29859472
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Therapeutic silencing of fat-specific protein 27 improves glycemic control in mouse models of obesity and insulin resistance.
    Langhi C; Arias N; Rajamoorthi A; Basta J; Lee RG; Baldán Á
    J Lipid Res; 2017 Jan; 58(1):81-91. PubMed ID: 27884961
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Modulation of xenobiotic nuclear receptors in high-fat diet induced non-alcoholic fatty liver disease.
    Li X; Wang Z; Klaunig JE
    Toxicology; 2018 Dec; 410():199-213. PubMed ID: 30120929
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pnpla3 silencing with antisense oligonucleotides ameliorates nonalcoholic steatohepatitis and fibrosis in Pnpla3 I148M knock-in mice.
    Lindén D; Ahnmark A; Pingitore P; Ciociola E; Ahlstedt I; Andréasson AC; Sasidharan K; Madeyski-Bengtson K; Zurek M; Mancina RM; Lindblom A; Bjursell M; Böttcher G; Ståhlman M; Bohlooly-Y M; Haynes WG; Carlsson B; Graham M; Lee R; Murray S; Valenti L; Bhanot S; Åkerblad P; Romeo S
    Mol Metab; 2019 Apr; 22():49-61. PubMed ID: 30772256
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Silencing of STE20-type kinase MST3 in mice with antisense oligonucleotide treatment ameliorates diet-induced nonalcoholic fatty liver disease.
    Caputo M; Kurhe Y; Kumari S; Cansby E; Amrutkar M; Scandalis E; Booten SL; Ståhlman M; Borén J; Marschall HU; Aghajan M; Mahlapuu M
    FASEB J; 2021 May; 35(5):e21567. PubMed ID: 33891332
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Fenofibrate, but not ezetimibe, prevents fatty liver disease in mice lacking phosphatidylethanolamine
    van der Veen JN; Lingrell S; Gao X; Takawale A; Kassiri Z; Vance DE; Jacobs RL
    J Lipid Res; 2017 Apr; 58(4):656-667. PubMed ID: 28159867
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Modulation Effect of Peroxisome Proliferator-Activated Receptor Agonists on Lipid Droplet Proteins in Liver.
    Zhu YX; Zhang ML; Zhong Y; Wang C; Jia WP
    J Diabetes Res; 2016; 2016():8315454. PubMed ID: 26770990
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of combined PPAR-γ and PPAR-α agonist therapy on fructose induced NASH in rats: Modulation of gene expression.
    Abd El-Haleim EA; Bahgat AK; Saleh S
    Eur J Pharmacol; 2016 Feb; 773():59-70. PubMed ID: 26825546
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Metabolic and hepatic effects of liraglutide, obeticholic acid and elafibranor in diet-induced obese mouse models of biopsy-confirmed nonalcoholic steatohepatitis.
    Tølbøl KS; Kristiansen MN; Hansen HH; Veidal SS; Rigbolt KT; Gillum MP; Jelsing J; Vrang N; Feigh M
    World J Gastroenterol; 2018 Jan; 24(2):179-194. PubMed ID: 29375204
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hepatic Mitochondrial SAB Deletion or Knockdown Alleviates Diet-Induced Metabolic Syndrome, Steatohepatitis, and Hepatic Fibrosis.
    Win S; Min RWM; Zhang J; Kanel G; Wanken B; Chen Y; Li M; Wang Y; Suzuki A; Aung FWM; Murray SF; Aghajan M; Than TA; Kaplowitz N
    Hepatology; 2021 Dec; 74(6):3127-3145. PubMed ID: 34331779
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Liver PPARα is crucial for whole-body fatty acid homeostasis and is protective against NAFLD.
    Montagner A; Polizzi A; Fouché E; Ducheix S; Lippi Y; Lasserre F; Barquissau V; Régnier M; Lukowicz C; Benhamed F; Iroz A; Bertrand-Michel J; Al Saati T; Cano P; Mselli-Lakhal L; Mithieux G; Rajas F; Lagarrigue S; Pineau T; Loiseau N; Postic C; Langin D; Wahli W; Guillou H
    Gut; 2016 Jul; 65(7):1202-14. PubMed ID: 26838599
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Fenofibrate alleviates NAFLD by enhancing the PPARα/PGC-1α signaling pathway coupling mitochondrial function.
    Wang X; Wang J; Ying C; Xing Y; Su X; Men K
    BMC Pharmacol Toxicol; 2024 Jan; 25(1):7. PubMed ID: 38173037
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Fenofibrate treatment attenuated chronic endoplasmic reticulum stress in the liver of nonalcoholic fatty liver disease mice.
    Zhang N; Lu Y; Shen X; Bao Y; Cheng J; Chen L; Li B; Zhang Q
    Pharmacology; 2015; 95(3-4):173-80. PubMed ID: 25896720
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Disruption of hepatic small heterodimer partner induces dissociation of steatosis and inflammation in experimental nonalcoholic steatohepatitis.
    Magee N; Zou A; Ghosh P; Ahamed F; Delker D; Zhang Y
    J Biol Chem; 2020 Jan; 295(4):994-1008. PubMed ID: 31831621
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lipid-lowering agents inhibit hepatic steatosis in a non-alcoholic steatohepatitis-derived hepatocellular carcinoma mouse model.
    Orime K; Shirakawa J; Togashi Y; Tajima K; Inoue H; Nagashima Y; Terauchi Y
    Eur J Pharmacol; 2016 Feb; 772():22-32. PubMed ID: 26724391
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Target Deconvolution of Fenofibrate in Nonalcoholic Fatty Liver Disease Using Bioinformatics Analysis.
    Mahmoudi A; Butler AE; Jamialahmadi T; Sahebkar A
    Biomed Res Int; 2021; 2021():3654660. PubMed ID: 34988225
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Docosahexaenoic acid blocks progression of western diet-induced nonalcoholic steatohepatitis in obese Ldlr-/- mice.
    Lytle KA; Wong CP; Jump DB
    PLoS One; 2017; 12(4):e0173376. PubMed ID: 28422962
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.